الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
Diabetes mellitus and its complications are rapidly becoming the world’s most significant cause of morbidity and mortality (Jang et al., 2011).
Diabetes mellitus is a leading cause of CKD. More than 35% of adults with DM develop kidney disease (De Boer et al., 2011).
The mineral bone disorder (MBD), which is a systemic disorder with both skeletal and extraskeletal consequences, has effect on morbidity and mortality in patients with CKD. The disordered mineral metabolism is more common and more severe in patients with diabetes mellitus. The difference of bone disease and higher prevalence of other systemic manifestations has a consequent concern in the treatment plan for CKD patients with type 2 diabetes mellitus (Kaul et al., 2012).
The aim of this study is to measure the levels of fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease patients with type 2 diabetes mellitus and verify the relationship between fgf23 and type 2 diabetes mellitus in CKD patients.
We selected 60 patients with chronic kidney disease and 20 healthy subjects as a control group. We divided them into 3 groups as follows:
group 1: 30 patients with CKD on conservative treatment with DM type 2.
group 2: 30 patients with CKD on conservative treatment but without DM.
group 3: 20 healthy subjects were enrolled in the study as a control group (age &sex matched).
We excluded CKD patients on hemodialysis, patients with other serious illness e.g. cardiovascular disease, atherosclerosis.